{"id":4647,"count":22,"description":"MedsBase-kategorien for situationel angstbehandling er en misforst\u00e5else v\u00e6rd at forst\u00e5.<\/strong> Hvert produkt p\u00e5 denne side er en psykiatrisk medicin til kronisk brug \u2014 antidepressiva (SSRI, SNRI, TCA), atypiske antipsykotika eller relaterede midler, der ordineres og titreres over uger for diagnosticerede hum\u00f8r-, angst- og psykotiske lidelser. Ingen af disse l\u00e6gemidler er f\u00f8rstevalg for akut, pr\u00e6stationsrelateret \u201csituationel\u201d angst<\/strong> (flying, public speaking, exams, interviews) — for those situations, the clinically appropriate options are short-acting beta-blockers (propranolol), benzodiazepines, and sedating antihistamines (hydroxyzine), none of which are stocked in this category. If your need is occasional acute anxiety only, the medications below are not the right starting point. If your need is a diagnosed depressive, anxiety, bipolar, or psychotic disorder requiring long-term treatment, the index below organises what is here by drug class.\n\nSSRIs — selective serotonin reuptake inhibitors\nFirst-line antidepressants worldwide for major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder, social anxiety disorder, OCD, PTSD, and PMDD. Onset 4–6 weeks for full mood response; anxiety symptoms often respond at 1–2 weeks. Common side effects are nausea, GI upset (usually transient), sexual dysfunction, and modest weight changes. Discontinuation must be tapered — never stopped abruptly.\n\nSertralin<\/strong> \u2014 det reneste CYP-profil blandt SSRI\u2019er og foretrukket under graviditet\/amning: Sertafine<\/a>, Sertagress<\/a>, Sertima<\/a>, Zosert<\/a> (50\/100 mg). Godkendt til MDD, OCD (voksne og b\u00f8rn), panik, social angst, PTSD, PMDD.\nParoxetine<\/strong> \u2014 Xepar<\/a> 20 mg. The SSRI with the broadest range of FDA-approved anxiety indications (MDD, GAD, social anxiety, panic, OCD, PTSD, PMDD). Trade-offs: worst discontinuation syndrome of the class (very short half-life), highest weight gain, highest sexual dysfunction, pregnancy category D.\n\n\nSNRIs — serotonin-norepinephrine reuptake inhibitors\nSecond main first-line antidepressant class. Venlafaxine<\/strong> (depottabletter) er godkendt til MDD, GAD, social angst og panikforstyrrelse. Mekanisme skifter med dosis: SSRI-lignende under 150 mg\/dag, \u00e6gte SNRI (med noradrenalin genoptagelsesh\u00e6mning) ved 150\u2013225 mg\/dag, med fuld effekt ved behandlingsresistent depression ved 225\u2013375 mg\/dag i MDD. S\u00e6rlige bekymringer: dosisafh\u00e6ngigt blodtryksstigning (overv\u00e5g blodtryk ved > 225 mg\/dag) og alvorligt oph\u00f8rssyndrom (obligatorisk udtrapning). Mere farlig ved overdosis end SSRI\u2019er.\n\nAffexor XR<\/a> \u00b7 Venish SR<\/a> \u00b7 Venpad XR<\/a> \u00b7 Ventab XL<\/a> — all venlafaxine extended-release in 37.5 \/ 75 \/ 150 mg strengths.\n\n\nTricyclic antidepressants (TCAs) and TCA-related anxiolytics\nOlder antidepressant class largely replaced by SSRIs\/SNRIs for first-line depression, but still useful for refractory depression, neuropathic pain, panic disorder, paediatric enuresis, and migraine prevention. Anticholinergic burden, sedation, orthostatic hypotension, and cardiac toxicity in overdose are the main concerns — baseline ECG before starting in patients over 50.\n\nD-mine<\/a> \u2014 imipramin 25 mg, det originale trizykliske antidepressivum; til MDD, panik, b\u00f8rneenurese, neuropatisk smerte.\nPrimox<\/a> \u2014 nortriptylin 25 mg, det sekund\u00e6re amin-TCA med den laveste antikolinerg byrde i klassen; f\u00f8rstevalgs trizyklikum til migr\u00e6neprofylakse og kronisk neuropatisk smerte.\nOpiprol<\/a> \u2014 opipramol 50 mg, et atypisk TCA-relateret anxiolytikum der ikke ikke<\/em> inhibit serotonin reuptake (its mechanism is sigma-receptor agonism plus antihistamine); primary use is generalised anxiety disorder and somatoform disorders, mostly in German-speaking Europe.\n\n\nAtypical antidepressants — mirtazapine, trazodone, vilazodone\nThree drugs with mechanisms outside the SSRI \/ SNRI \/ TCA paradigm.\n\nNasdep<\/a> \u2014 mirtazapin 30 mg, et tetracyclisk NaSSA med st\u00e6rk H1-antihistamin aktivitet. Paradoksal sedationsm\u00f8nster (mere sedativ ved 15 mg end 45 mg). Betydelig v\u00e6gt\u00f8gning. Bedst egnet til MDD med s\u00f8vnl\u00f8shed, nedsat appetit eller v\u00e6gttab, hvor bivirkningerne virker for patienten snarere end imod dem.\nTrazalon<\/a>, Trazonil<\/a>, Tridon<\/a> \u2014 trazodon (50\/100 mg). Godkendt til MDD, men den dominerende moderne anvendelse er off-label lavdosis (25\u2013100 mg) til kronisk s\u00f8vnl\u00f8shed. Ingen afh\u00e6ngighedspotentiale; hovedbekymringer er ortostatisk hypotension (alfa-1-blokering), priapisme hos m\u00e6nd (sj\u00e6ldent 1 ud af 1.000\u201310.000 \u2014 akut hvis > 4 timer) og QT-forl\u00e6ngelse ved h\u00f8jere doser.\nVilano<\/a> \u2014 vilazodon 40 mg, en SSRI plus 5-HT1A-partiel agonist med f\u00e6rre seksuelle bivirkninger end andre SSRIs. Skal indtages med et m\u00e5ltid p\u00e5 \u2265 500 kalorier<\/strong> — bioavailability halves on an empty stomach.\n\n\nAtypical antipsychotics\nSecond-generation antipsychotics for schizophrenia, bipolar disorder, and adjunctive treatment of treatment-resistant depression. All carry an FDA black-box warning for increased mortality in elderly with dementia-related psychosis. Monitor weight, fasting glucose, and lipids at baseline, 3 months, then annually (metabolic syndrome is a class risk).\n\nPsyquit<\/a> \u00b7 Q-Siz SR 400<\/a> \u2014 quetiapin i \u00f8jeblikkelig- og forl\u00e6ngetvirkende formuleringer. Kraftig sedering; brede indikationer (skizofreni, bipolar mani og depression, MDD-adjuvans).\nRiscon<\/a> \u2014 risperidon til skizofreni, bipolar mani og irritabilitet ved autisme. Karakteristisk bivirkning: h\u00f8jest hyperprolaktin\u00e6mi blandt de atypiske antipsykotika (galaktor\u00e9, gyn\u00e6komasti, amenor\u00e9, seksuel dysfunktion). Giver typisk-antipsykotisk-lignende EPS ved doser > 6 mg\/dag.\nZipsydon<\/a> \u2014 ziprasidon til skizofreni og bipolar mani. Laveste metaboliske belastning blandt de almindelige atypiske antipsykotika (mindre v\u00e6gt\u00f8gning, mindre p\u00e5virkning af glukose\/lipider) men h\u00f8jeste QT-forl\u00e6ngelse (basal ECG er obligatorisk). Skal indtages med et m\u00e5ltid p\u00e5 \u2265 500 kalorier<\/strong>.\n\n\nFirst-generation antipsychotic + anticholinergic combination\nTrinicalm Plus<\/a> — trifluoperazine 5 mg + trihexyphenidyl 2 mg. A high-potency typical antipsychotic paired with an anticholinergic anti-Parkinson agent to pre-empt the EPS (parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics routinely cause. Used where typical antipsychotics remain first-line by cost or availability and in stable legacy regimens. Modern practice generally favours atypical antipsychotic monotherapy where available — lower EPS risk, lower tardive dyskinesia risk, and no routine anticholinergic cover required. Trihexyphenidyl has recognised abuse potential at supratherapeutic doses.\n\nHow to choose\nFor untreated MDD or anxiety disorders without prior treatment, sertralin<\/strong> er det mest forsvarlige f\u00f8rstevalg p\u00e5 grund af ren medicininteraktionsprofil, brede indikationer og sikkerhed under graviditet\/amning. Ved MDD med udtalet insomni, nedsat appetit eller v\u00e6gttab, mirtazapin<\/strong> is a sensible alternative because the side effects work in the patient's favour. For chronic insomnia not responding to behavioural interventions, low-dose trazodon<\/strong> det mest ordinerede off-label hypnotikum globalt. Ved skizofreni eller bipolar I-lidelse er et atypisk antipsykotikum (quetiapin, risperidon, ziprasidon) f\u00f8rstevalg frem for typiske antipsykotika i moderne praksis. Ingen af disse l\u00e6gemidler erstatter individuel psykiatrisk vurdering<\/strong> \u2014 det rigtige valg afh\u00e6nger af diagnose, komorbiditet, tidligere behandlingshistorie, medicininteraktioner og graviditetsstatus.\n\n\u00c6gte WHO-GMP-certificeret fabrikantlager \u00b7 diskret emballage \u00b7 verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ kunder i 50+ lande.<\/strong> Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/a>.","link":"https:\/\/medsbase.com\/da\/situational-anxiety-treatment\/","name":"Behandling af situationel angst","slug":"situational-anxiety-treatment","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat\/4647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product?product_cat=4647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}